A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

NCT00913835 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

BIOLOGICAL: Olaratumab
DRUG: liposomal doxorubicin

Sponsor

Eli Lilly and Company